Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 2 Published - 14:00 UTC    08:00 EST    13-February-2001      
Issue 44 * Next Update - 14:00 UTC 08:00 EST    14-February-2001      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Back To Vidyya Today In Vidyyasm

Vidyya Medical News Service For 13-February-2001:

The following stories appear in full on Today's Vidyya Medical News Service Web site.

Today's Vidyya should catch you up on some of the latest-breaking pharmaceutical industry news:

Hypothyroidism, a disease in which the thyroid gland does not produce sufficient thyroxine, affects up to 24% of the older population, most of them women. Symptoms range from cold intolerance and weight gain to cardiovascular disease and dementia. It is estimated that 8 million people are being treated with levothyroxine sodium, familiar to most people as the drug Synthroid® (levothyroxine sodium tablets, USP). Synthroid, the #3 prescribed brand in America, with an estimated 85% share of the market, does not have the approved New Drug Application (NDA) it needs to remain on the market. A different brand, Unithroid (levothyroxine sodium tablets, USP) received its NDA in August of 2000 and is the only oral levothyroxine sodium product approved as safe and effective by the FDA.

For more information: The Third Most Prescribed Drug In The US Lacks Necessary Approval To Remain On Market

Eli Lilly and Company announced today that results of a phase III clinical trial show drotrecogin alfa --proposed brand name, zovant--reduced the relative risk of death from sepsis with associated acute organ dysfunction (known as severe sepsis) by 19.4 percent. The new data, published today on The New England Journal of Medicine's website (www.nejm.org), are from the PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) trial.

For more information: Promising New Sepsis Drug Performs Well In Phase III Clinical Trials

The drug raloxifene significantly reduces the risk of invasive breast cancer in post-menopausal women, according to results of a large-scale study involving the University of Pittsburgh Graduate School of Public Health (GSPH) and published in the upcoming issue of Breast Cancer Research and Treatment. The Multiple Outcomes of Raloxifene Evaluation (MORE) trial measured the effects of raloxifene, which has been approved by the U.S. Food and Drug Administration for the prevention and treatment of osteoporosis, on breast cancer rates after four years of follow-up. The results confirm the study's preliminary findings, which where published in the June 1999 issue of the Journal of the American Medical Association.

For more information: Review: Management Of Patients With Suspected Viral Hemorrhagic Fever

Evista ® is a prescription medicine used by women after menopause to treat or prevent osteoporosis. Patients should take Calcium and vitamin D along with Evista ® if they do not get enough calcium and vitamin D in their diet. Evista ® treats osteoporosis by helping make bones stronger and less likely to break. It helps prevent osteoporosis by building bone and stopping the thinning of bone that occurs after menopause. Throughout Evista's history, speculation that it might be a powerful anti-breast cancer agent has surfaced. Learn more about the drug with this prescribing information.

For more information: Prescribing Information: Raloxifene (Evista ®)

Watson Pharmaceuticals, Inc. announced today that the Food and Drug Administration (FDA) has approved two of Watson's abbreviated new drug applications: Oxaprozin Tablets, 600 mg and Methylphenidate Hydrochloride Extended Releases Tablets USP, 20 mg.

For more information: Generic Forms Of Daypro ® And Ritalin ® Approved By FDA

Today's Vidyya articles are:

As always, we hope you enjoy the issue.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.